Outset Medical (OM) to Release Earnings on Thursday

Outset Medical (NASDAQ:OM) is expected to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Outset Medical to announce earnings of ($0.7167) per share and revenue of $28.9670 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Outset Medical (NASDAQ:OM) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.04). Outset Medical had a negative net margin of 63.65% and a negative return on equity of 56.13%. The firm had revenue of $27.86 million during the quarter, compared to analysts’ expectations of $28.90 million. On average, analysts expect Outset Medical to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Outset Medical Price Performance

Shares of NASDAQ OM opened at $4.99 on Tuesday. Outset Medical has a twelve month low of $3.00 and a twelve month high of $17.20. The stock’s 50 day moving average price is $4.56 and its 200-day moving average price is $4.27. The company has a market capitalization of $92.51 million, a PE ratio of -1.20 and a beta of 1.96. The company has a quick ratio of 4.97, a current ratio of 6.29 and a debt-to-equity ratio of 0.87.

Insider Buying and Selling

In related news, CFO Renee Gaeta sold 17,672 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $4.94, for a total value of $87,299.68. Following the transaction, the chief financial officer owned 113,753 shares in the company, valued at approximately $561,939.82. This represents a 13.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 25,337 shares of company stock valued at $115,660 in the last quarter. 2.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OM. Los Angeles Capital Management LLC purchased a new position in shares of Outset Medical in the fourth quarter worth about $29,000. Legal & General Group Plc bought a new stake in shares of Outset Medical in the second quarter valued at approximately $34,000. BNP Paribas Financial Markets lifted its stake in shares of Outset Medical by 7,013.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after buying an additional 2,034 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Outset Medical during the 4th quarter valued at approximately $46,000. Finally, HRT Financial LP bought a new position in Outset Medical in the 4th quarter worth approximately $58,000.

Analysts Set New Price Targets

OM has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a report on Wednesday, June 24th. Wall Street Zen downgraded Outset Medical from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Outset Medical in a research report on Friday, May 8th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $10.00.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.